Standout Papers
- Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. (1976)
- Development of a Crohn's Disease Activity Index (1976)
Citation Impact
Citing Papers
Induction of Colonic Regulatory T Cells by Indigenous Clostridium Species
2010 StandoutScience
Incorporation of azides into recombinant proteins for chemoselective modification by the Staudinger ligation
2001 StandoutNobel
MHC-Restricted Cytotoxic T Cells: Studies on the Biological Role of Polymorphic Major Transplantation Antigens Determining T-Cell Restriction-Specificity, Function, and Responsiveness
1979 StandoutNobel
Elemental diet as primary treatment of acute Crohn's disease: a controlled trial.
1984
Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
1989
Polyclonal nature of the intestinal mucosal lymphocyte populations in inflammatory bowel disease
1988
Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease.
1986
Activation of nuclear factor κB in inflammatory bowel disease
1998
Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
1994
A controlled double blind study of azathioprine in the management of Crohn's disease.
1995
Low dose steroids and clinical relapse in Crohn's disease: a controlled trial.
1978
Double blind, placebo controlled trial of metronidazole in Crohn's disease.
1991
Ten years' experience with an elemental diet in the management of Crohn's disease.
1990
Prospective comparison of faecal incontinence grading systems
1999 Standout
Triple-Negative Breast Cancer
2010 Standout
A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease
2000
Antibiotic Use in Crohnʼs Disease
1997
Maintenance treatment of Crohn's disease
2003
Infliximab Plus Azathioprine for Steroid-Dependent Crohn’s Disease Patients: A Randomized Placebo-Controlled Trial
2006
Systemic and topical steroids in inflammatory bowel disease
2004
European evidence based consensus on the diagnosis and management of Crohn’s disease: current management
2006
Infliximab for acute, not steroid-refractory ulcerative colitis
2004
A Multicenter, Randomized, Double-Blind Trial of EverolimusVersusAzathioprine and Placebo to Maintain Steroid-Induced Remission in Patients With Moderate-to-Severe Active Crohn's Disease
2008
Inflammation and cancer
2002 StandoutNature
Management of Crohn's disease in adults
2001
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
2001
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
1999 Standout
Correlation between endoscopic severity and the clinical activity index in ulcerative colitis
1998
The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells
2006 Standout
Efficacy of cyclosporine in treatment of fistula of crohn's disease
1994
Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients
2001
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
2009 StandoutNature
Combined budesonide and antibiotic therapy for active Crohn's disease: A randomized controlled trial
2002
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials
2009
Natalizumab Induction and Maintenance Therapy for Crohn's Disease
2005
Meta-analysis of enteral nutrition as a primary treatment of active crohn's disease
1995
Low counts of Faecalibacterium prausnitzii in colitis microbiota
2009
Unravelling the pathogenesis of inflammatory bowel disease
2007 StandoutNature
Long-term treatment of rectovaginal fistulas in Crohn’s disease: Response to infliximab in the ACCENT II Study
2004
CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial
2004
A Randomized, Double-Blind, Controlled Withdrawal Trial in Crohn’s Disease Patients in Long-term Remission on Azathioprine
2005
Successful Treatment of Recalcitrant Chronic Idiopathic Urticaria With Sulfasalazine
2006
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease
2007
Immunohistochemical examination for mycobacteria in intestinal tissues from patients with Crohn's disease
1989
Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study
2001
Mucin O-glycans facilitate symbiosynthesis to maintain gut immune homeostasis
2019
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease
2000
Inflammatory bowel disease: clinical aspects and established and evolving therapies
2007 Standout
Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon
2003
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
2012
Risk of Infectious Complications in Patients Taking Glucocorticosteroids
1989 Standout
Comparative Tolerability of Treatments for Inflammatory Bowel Disease
2000
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
2014
Circulating soluble intercellular adhesion molecule-1 (sICAM-1) in active inflammatory bowel disease
1994
Oral Budesonide for Active Crohn's Disease
1994
The jejunal secretion of histamine is increased in active Crohn's disease
1990
The effect of elemental diet on intestinal permeability and inflammation in Crohn's disease
1991
Natalizumab for Active Crohn's Disease
2003
CDP571, a humanized monoclonal antibody to tumour necrosis factor‐α, for steroid‐dependent Crohn's disease: a randomized, double‐blind, placebo‐controlled trial
2006
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
2001 StandoutNature
A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease
1997 Standout
The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study
2001 Standout
A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn’s Disease
2005
Increased expression of interleukin 17 in inflammatory bowel disease
2002
Tacrolimus for the treatment of fistulas in patients with crohn’s disease: a randomized, placebo-controlled trial
2003
Structure-guided mutagenesis of a mucin-selective metalloprotease from Akkermansia muciniphila alters substrate preferences
2022 StandoutNobel
Disease Activity Courses in a Regional Cohort of Crohn's Disease Patients
1995
Randomized, controlled trial of recombinant human interleukin‐11 in patients with active Crohn's disease
2002
Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s disease
2005
Smoking cessation and the course of Crohn's disease: An intervention study
2001
Role of the Microbiota in Immunity and Inflammation
2014 Standout
Mechanisms in failure of infliximab for Crohn's disease
2000
A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
2008
Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European cooperative Crohn's disease study VI
2000
Serum antibodies to mycobacterial antigens in active Crohn's disease
1988
Antibodies to cytoskeletal proteins in patients with Crohn's disease
1990
A Phase I Trial With Transgenic Bacteria Expressing Interleukin-10 in Crohn’s Disease
2006
Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
2008
Onercept for Moderate-to-Severe Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
2006
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
2001 StandoutNature
Polyclonal nature of the intestinal mucosal lymphocyte populations in inflammatory bowel disease
1988
Mesalamine in the treatment of mild to moderate active Crohn's ileitis: Results of a randomized, multicenter trial
1999
Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection.
1996 StandoutNobel
Pathogenic Yersinia DNA Is Detected in Bowel and Mesenteric Lymph Nodes From Patients With Crohn's Disease
2003
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
2004 Standout
Inflammatory Bowel Disease
2002 Standout
A meta-analysis of the placebo rates of remission and response in clinical trials of active crohn’s disease
2004
Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial
2007
Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin
2003
Inflammatory Bowel Disease
1991
High Prevalence of Antibodies to Intestinal Epithelial Antigens in Patients with Inflammatory Bowel Disease and Their Relatives
1989
Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease
1997
The influence of zinc status and malnutrition on immunological function in Crohn's disease
1991
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease
2004
Certolizumab Pegol for the Treatment of Crohn's Disease
2007
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
2002 Standout
Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice
1994 StandoutNature
Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial
2006
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease
2004
Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif.
1995 StandoutNobel
Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation
1991
Selected loss of tolerance evidenced by Crohn's disease–associated immune responses to auto- and microbial antigens
2002
Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis
2004 Standout
In vitro induction of chromosome damage by sulphasalazine in human lymphocytes
1989
Development, Validation, and Evaluation of a Pediatric Ulcerative Colitis Activity Index: A Prospective Multicenter Study
2007 Standout
Molecular portraits of human breast tumours
2000 StandoutNature
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
2010
Intestinal permeability and the prediction of relapse in Crohn's disease
1993
A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease
2000
An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
1999
Oral pentasa in the treatment of active Crohn’s disease: A meta-analysis of double-blind, placebo-controlled trials
2004
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease
1999
Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial
2008
Childhood Factors in Ulcerative Colitis and Crohn's Disease: An International Cooperative Study
1987
6-Mercaptopurine in the Management of Inflammatory Bowel Disease: Short- and Long-Term Toxicity
1989
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease
2000
A prospective trial comparing small bowel radiographs and video capsule endoscopy for suspected small bowel disease
2002 Standout
A microbial symbiosis factor prevents intestinal inflammatory disease
2008 StandoutNature
Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease
1999
A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active crohn's disease
2001
An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial
2001
Dissection of the Inflammatory Bowel Disease Transcriptome Using Genome-Wide cDNA Microarrays
2005
Inflammatory bowel disease: Etiology and pathogenesis
1998 Standout
Anti–Interleukin-12 Antibody for Active Crohn's Disease
2004
Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
1999
Systematic review: the effectiveness of budesonide therapy for Crohn's disease
2002
A Preliminary Study of Growth Hormone Therapy for Crohn's Disease
2000
Pediatric Crohn Disease Activity Index: Responsive to Short-term Change
2003
Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease
1994
AGA technical review on perianal Crohn’s disease
2003
Impaired Peripheral Th1 CD4+ T Cell Response to Escherichia coli Proteins in Patients with Crohn’s Disease and Ankylosing Spondylitis
2011
Repifermin (keratinocyte growth factor‐2) for the treatment of active ulcerative colitis: a randomized, double‐blind, placebo‐controlled, dose‐escalation trial
2003
A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease☆
2004
Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease
2002
Methotrexate for the Treatment of Crohn's Disease
1995
The inflammatory reflex
2002 StandoutNature
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
2010
Increased collagen type III synthesis by fibroblasts isolated from strictures of patients with Crohn's disease
1992
Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease
1994
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
2010 Standout
A phase 1/2A Trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohnʼs disease
2006
HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release.
1995 StandoutNobel
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
2013 Standout
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease
2006
American Gastroenterological Association Institute Technical Review on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel Disease
2006
Management of Crohn's Disease in Adults
2009 Standout
Budesonide for Maintenance of Remission in Patients with Crohn's Disease in Medically Induced Remission: A Predetermined Pooled Analysis of Four Randomized, Double-Blind, Placebo-Controlled Trials
2005
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease
2002
Effect of an Enteric-Coated Fish-Oil Preparation on Relapses in Crohn's Disease
1996
Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn’s disease
2004
The limitations of corticosteroid therapy in Crohn’s disease
2001
Guidelines for the management of inflammatory bowel disease in adults
2004
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
2005 Standout
A Comparison of Budesonide and Mesalamine for Active Crohn's Disease
1998
Diminished neutrophil function in Crohn's disease and ulcerative colitis identified by decreased oxidative metabolism and low superoxide dismutase content.
1988
Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience.
1993
A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe Crohn’s disease
2006
Controlled trial comparing two types of enteral nutrition in treatment of active Crohn's disease: elemental versus polymeric diet.
1991
A critical role for neutralizing-antibody-producing B cells, CD4+T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: Implications for adoptive immunotherapy of virus carriers
1997
Mechanisms of Cell Protection by Heme Oxygenase-1
2010 Standout
The mouse T cell receptor: Structural heterogeneity of molecules of normal T cells defined by Xenoantiserum
1983 StandoutNobel
European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment
1984
Host-Bacterial Mutualism in the Human Intestine
2005 StandoutScience
Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID).
1989
Maintenance Therapy in Crohn's Disease
2000
A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY
1980 Standout
T cell-mediated hepatitis in mice infected with lymphocytic choriomeningitis virus. Liver cell destruction by H-2 class I-restricted virus-specific cytotoxic T cells as a physiological correlate of the 51Cr-release assay?
1986
Expression in transgenic mice of class I histocompatibility antigens controlled by the metallothionein promoter.
1989 StandoutNobel
The isolation and nucleotide sequence of a cDNA encoding the T cell surface protein T4: a new member of the immunoglobulin gene family
1985 StandoutNobel
Sargramostim for Active Crohn's Disease
2005
Comparison of enteral nutrition and drug treatment in active Crohn's disease
1991
Commensal Host-Bacterial Relationships in the Gut
2001 StandoutScience
[American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease].
2007
Complex formation of class I transplantation antigens and a viral glycoprotein.
1983 StandoutNobel
Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease
2016
Discovery of aminoacyl-tRNA synthetase activity through cell-surface display of noncanonical amino acids
2006 StandoutNobel
Disease Tolerance as a Defense Strategy
2012 StandoutScience
Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD)
1995
Correlation between endoscopic severity and the clinical activity index in ulcerative colitis
1998
T-cell activation in Crohn's disease
1990
Vigorous HIV-1-Specific CD4 + T Cell Responses Associated with Control of Viremia
1997 StandoutScience
Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell Tolerance
2002 StandoutNobel
Possible role of Mycobacteria in inflammatory bowel disease
1984
T-cell activation in Crohn's disease. Increased levels of soluble interleukin-2 receptor in serum and in supernatants of stimulated peripheral blood mononuclear cells.
1990
Treatment of Crohn's Disease with 6-Mercaptopurine
1980
Commensal bacteria as targets in Crohn's disease
2000
Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab
2007
MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands
2010 StandoutNobel
Infliximab for the treatment of fistulas in patients with Crohn's disease
1999
Assessment of disease activity in inflammatory bowel disease; relevance for clinical trials.
2003
Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine
1996
Validation of the interleukin-10 knockout mouse model of colitis: antitumour necrosis factor-antibodies suppress the progression of colitis
2003
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Frequency of glucocorticoid resistance and dependency in Crohn's disease.
1994
The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase.
1968 Standout
Antibodies to cytoskeletal proteins in patients with Crohn's disease
1990
Crohn's disease and the mycobacterioses: a review and comparison of two disease entities
1989
Works of John W. Singleton being referenced
Azathioprine-related pancreatitis in patients with Crohn's disease.
1979
Clinical activity assessment in inflammatory bowel disease
1987
Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease
1999
Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial
1993
Development of a Crohn's Disease Activity Index
1976 Standout
Azathioprine-related pancreatitis in patients with Crohn's disease
1979
Developments in gastroenterology, vol. 1: Recent advances in Crohn's disease
1982
A trial of sulfasalazine as adjunctive therapy in Crohn's disease
1979
Patients with active Crohn's disease have elevated serum antibodies to antigens of seven enteric bacterial pathogens.
1984
National Cooperative Crohn's Disease Study: Study design and conduct of the study
1979
Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI)
1979
Biliverdin Reductase of Guinea Pig Liver
1965
Patients with active Crohn's disease have elevated serum antibodies to antigens of seven enteric bacterial pathogens
1984
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.
1976 Standout
Radiographic findings of the National Cooperative Crohn's Disease Study
1979
Azathioprine has a very limited role in the treatment of Crohn's disease
1981
National Cooperative Crohn's Disease Study: Adverse reactions to study drugs
1979
Immunotherapy with antibody, lymphocytes and transfer factor in chronic hepatitis B
1974
National Cooperative Crohn's Disease Study: Results of drug treatment
1979